F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML) (AML F18-FLT)
|ClinicalTrials.gov Identifier: NCT01592266|
Recruitment Status : Unknown
Verified April 2012 by Hadassah Medical Organization.
Recruitment status was: Not yet recruiting
First Posted : May 7, 2012
Last Update Posted : May 7, 2012
PET/CT is reliable tool in evaluation of treatment response in number cancers. F18-FLT is a precursor of DNA with high uptake in the bone marrow as a part of normal biodistribution. Highly increased uptake of this radiopharmaceutical was shown in a number of hematologic disease either in bone marrow or extramedullary.
F18-FLT PET/CT can provide a tool for whole body assessment of activity in bone marrow as well as early estimation of treatment efficacy or lack of it. In addition, this noninvasive study can replace bone marrow biopsy and predict response vs. non response to therapy.
|Condition or disease|
|Acute Myeloid Leucemia|
|Study Type :||Observational|
|Estimated Enrollment :||10 participants|
|Official Title:||F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With AML|
|Study Start Date :||October 2012|
|Estimated Primary Completion Date :||October 2013|
patients with AML prior and after treatment
- Measure of extent and intensity ( by standardized uptake value - SUV) of disease in bone marrow demonstrated on PET/CT images before and after treatment.
- prediction of treatment response by dynamics of FLT uptake(by SUV)in comparison to bone marrow biopsy
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01592266
|Contact: Marina Orevi, MDemail@example.com|
|Hadassah Hebrew University Medical Center||Not yet recruiting|
|Principal Investigator: Marina Orevi, MD|